Intervention

Maraviroc

ClinicalTrials.gov intervention label

Clinical trials53

Recruiting2

Common conditions25

Lead sponsors shown15

Clinical trials

53 shown

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without AntiretroviralsNCT06805656 · 2026-07-15

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...NCT05470491 · 2023-01-26

The Role of Home Packs of HIV PEPSE in High Risk IndividualsNCT04965662 · 2018-01-01

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 InfectionNCT02778204 · 2017-06-05

Maraviroc Efficacy for Hepatitis CNCT02881762 · 2017-06-01

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIVNCT03129113 · 2017-03-01

Impact of CCR5 Blockade in HIV+ Kidney Transplant RecipientsNCT02741323 · 2017-01-01

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)NCT02480894 · 2015-07-07

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing CureNCT02961829 · 2015-07-01

Maraviroc and NeuroAIDS PathogenesisNCT02159027 · 2015-06-01

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionNCT02475915 · 2015-01-01

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal ExplantsNCT02039323 · 2014-02-01

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of MaravirocNCT01894776 · 2013-06-01

Switching Undetectables to SelzentryNCT01866267 · 2013-01-01

First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy VolunteersNCT01719627 · 2012-10-01

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy SubjectsNCT01597895 · 2012-07-01

Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk WomenNCT01505114 · 2012-06-01

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected PatientsNCT02934022 · 2012-06-01

Maraviroc Abacavir STudy - Effect on Endothelial RecoveryNCT01389063 · 2012-01-01

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™NCT01597648 · 2011-11-01

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic StudyNCT01348763 · 2011-10-01

A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)NCT01449006 · 2011-10-01

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1NCT01345630 · 2011-09-01

Maraviroc Switch Collaborative StudyNCT01384682 · 2011-08-01

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis BNCT01327547 · 2011-05-18

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy SubjectsNCT01290211 · 2011-04-01

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)NCT01276236 · 2011-03-09

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)NCT01133210 · 2011-01-01

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy SubjectsNCT01140412 · 2010-07-01

Effect Of Maraviroc On The Pharmacokinetics Of DigoxinNCT01056874 · 2010-03-01

PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing RegimenNCT01190293 · 2010-01-01

Effect of Maraviroc on Endothelial Function in HIV-Infected PatientsNCT00844519 · 2010-01-01

Safety Study of Maraviroc's Effect on Human OsteoclastsNCT01428986 · 2009-11-01

The St. Marys and The Mater Switch StudyNCT00981773 · 2009-09-01

The Maraviroc Central Nervous System (CNS) StudyNCT00982878 · 2009-09-01

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029NCT00801515 · 2009-08-01

NO_LONGER_AVAILABLE

Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel AntigensNCT01049204 · 2009-07-01

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic ChildrenNCT00791700 · 2009-04-22

Maraviroc in Immunological Non-Responder (INR) HIV-1-infected SubjectsNCT00884858 · 2009-04-01

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/EmtricitabineNCT00808002 · 2009-02-01

Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic SuppressionNCT00709111 · 2009-01-01

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell RecoveryNCT00925756 · 2008-10-20

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic FailureNCT00735072 · 2008-09-01

Maraviroc Compassionate UseNCT00719823 · 2008-08-01

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal FunctionNCT00717067 · 2008-07-01

Maraviroc 300 mg Twice Daily in HIV Negative Male VolunteersNCT00771823 · 2008-05-01

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal TissueNCT00775294 · 2008-05-01

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving MaravirocNCT00853840 · 2008-04-01

Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleNCT00537394 · 2008-01-01

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)NCT00525733 · 2007-10-01

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With MaravirocNCT00703586 · 2007-09-01

Multicenter, Safety Study Of MaravirocNCT00478231 · 2007-07-01

Maraviroc in Rheumatoid ArthritisNCT00427934 · 2007-02-01

Common conditions

Leading sponsors

ViiV Healthcare13 National Institute of Allergy and Infectious Diseases (NIAID)4 Imperial College London3 St Stephens Aids Trust3 University of California, San Francisco3 Federal University of São Paulo2 Rockefeller University2 University of North Carolina, Chapel Hill2 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1 ASST Fatebenefratelli Sacco1 Bruce Brew1 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia1 Germans Trias i Pujol Hospital1 GlaxoSmithKline1 Guy's and St Thomas' NHS Foundation Trust1

Trial status mix

COMPLETED42

TERMINATED5

RECRUITING2

UNKNOWN2

NO_LONGER_AVAILABLE1

WITHDRAWN1

Phase mix

PHASE118

PHASE415

PHASE210

PHASE38

NA4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.